Table 1.
Baseline Characteristics for the Overall Cohort Stratified According to Rs10985126 (n=831) *
| Baseline Characteristics | All (n=831) | hc of Major Allele (n=563) | Heterozygotes (n=246) | hc of Minor Allele (n=22) | p |
|---|---|---|---|---|---|
| Age (mean±SD) | 68 (±12) | 68 (±11) | 69 (±12) | 71 (±10) | 0.578 |
| No. of males | 590 (71%) | 401 (71%) | 176 (72%) | 13 (59%) | 0.442 |
| Cardiovascular risk factors | |||||
| Arterial hypertension | 693 (83%) | 463 (82%) | 211 (86%) | 19 (86%) | 0.259 |
| Hyperlipidemia | 483 (58%) | 334 (59%) | 139 (57%) | 10 (45%) | 0.331 |
| Diabetes mellitus type 2 | 273 (33%) | 189 (34%) | 75 (30%) | 9 (41%) | 0.579 |
| Smoking | 338 (41%) | 234 (42%) | 96 (39%) | 8 (36%) | 0.783 |
| Clinical factors | |||||
| Left ventricular ejection fraction [%] (mean±SD) | 51 (±11) | 51 (±11) | 51 (±11) | 52 (±12) | 0.819 |
| Creatinine [mg/dl] (mean±SD) | 1.0 (±0.6) | 1.0 (±0.7) | 1.0 (±0.4) | 1.4 (±1.0) | 0.037 |
| Medication on admission | |||||
| Acetylsalicylic acid | 461 (55%) | 301 (53%) | 143 (58%) | 17 (77%) | 0.033 |
| Clopidogrel | 103 (12%) | 68 (12%) | 31 (13%) | 4 (18%) | 0.647 |
| Prasugrel | 17 (2%) | 14 (2%) | 3 (1%) | 0 (0%) | 0.396 |
| Ticagrelor | 37 (4%) | 22 (4%) | 14 (6%) | 1 (5%) | 0.539 |
| Oral anticoagulation | 68 (8%) | 47 (8%) | 18 (7%) | 3 (14%) | 0.568 |
| ACE-inhibitors | 354 (43%) | 236 (42%) | 108 (44%) | 10 (45%) | 0.886 |
| Angiotensin-II-receptor antagonists | 151 (18%) | 100 (18%) | 44 (18%) | 7 (32%) | 0.250 |
| Ca-channel-blocker | 168 (20%) | 102 (18%) | 61 (25%) | 5 (23%) | 0.103 |
| Beta blockers | 471 (57%) | 312 (55%) | 140 (57%) | 19 (86%) | 0.018 |
| Statins | 396 (48%) | 269 (48%) | 113 (46%) | 14 (64%) | 0.275 |
| Reason of admission | |||||
| ACS | 411 (49%) | 285 (51%) | 116 (47%) | 10 (45%) | 0.616 |
| Stable CAD | 420 (51%) | 278 (49%) | 130 (53%) | 12 (55%) | 0.616 |
Notes: *2 missing values. Bold indicates the values with statistical significance.